Raise Timeline
From Capital to Clinical Proof
The $1.0M pre-seed funds 12–15 months of operation. Every dollar is deployed against a single thesis: prove that practitioner-referred patients convert, retain, and compound, then scale.
Raise
$1.0M
Pre-Seed SAFE
Runway
12–15mo
Capital deployment
12-Month Target
$410K
Normalized MRR
Practitioners
400
By Q1 2027
Pre-Seed Raise
Mere is raising $1.0M via SAFE at a $9M post-money valuation cap. Capital is deployed against manufacturing readiness, platform development, and practitioner activation infrastructure.
$1.0M SAFE raise, investor outreach and close
SAFE agreement execution with qualified investors
Capital deployment planning finalized
Clinic-First Launch
Launch NanoActives subscription through 20 owned and VUIM-affiliated clinics. Validate trial-to-paid conversion and initial retention in a controlled clinical environment before scaling distribution.
20 practitioners activated in owned clinics (VA, NJ, GA)
Trial pack dispensing live - $9.99 / 7-day protocols
Subscription fulfillment operational - $79/month
First paid subscriber cohorts begin 30-day retention tracking
NORA AI IRB replication study initiated (N=200 concordance validation)
Capital Deployed: ~$280K manufacturing & inventory, ~$290K product & engineering
Network Expansion
Scale practitioner activation from 20 to 300 through VUIM alumni network. Standardized enablement kits and trial pack seeding drive adoption across 20+ states.
120 activated practitioners by end of Q3 2026
300 activated practitioners by end of Q4 2026
Trial throughput scaling: 14–17 trials per practitioner per month
Base case: 22.5% trial-to-paid conversion validated with production cohorts
Practitioner tiering active - 25% revenue share at 25+ subscribers
Mere App beta deployment to active subscribers
Capital Deployed: ~$240K marketing & content, ongoing manufacturing replenishment
Scale & Ring Gate Assessment
Reach 400 activated practitioners and assess readiness for Mere Pulse ring introduction. Ring launch is metric-gated, not calendar-gated, triggered only when subscription retention metrics are proven.
400 activated practitioners operational
Target: 5,316 active subscribers (base case)
Target: $410K normalized MRR (month 12)
Ring gate assessment: $150K+ MRR sustained for 2 consecutive months
Ring gate assessment: 5% monthly churn or better validated
Seed round positioning based on demonstrated unit economics
Mere Pulse Introduction
Introduce Mere Pulse smart ring to subscribers who have demonstrated retention. The ring deepens the closed-loop data moat, it does not precede proven subscription economics. Ring revenue is excluded from the 12-month forecast.
Mere Pulse ring production (1,000-unit pilot batch)
$299 per ring - $152–$160 contribution margin per unit
Closed-loop system fully operational: Measure → Interpret → Deliver → Adapt
30-day adaptive formulation cycle begins with biometric data integration
DTC channel assessment, transition from B2B2C to direct-to-consumer
Capital Allocation
Manufacturing & Inventory
Trial kits, ring pilot, fulfillment
Product & Engineering
Platform, app, data infrastructure
Marketing & Content
Video, practitioner enablement
Working Capital
Salaries, G&A, runway buffer
Investment Process
For accredited investors interested in participating in the Mere pre-seed round.
Review Materials
Review this platform, the investor presentation, and financial model. Access the data room for detailed diligence documents.
Schedule Discussion
Contact Byung Kim (byung@mere.co) to schedule a conversation with the founding team and discuss the opportunity in detail.
Diligence & Documentation
Complete your diligence process. Mere will provide the SAFE agreement and supporting documentation for review by your legal counsel.
Execute & Fund
Sign the SAFE agreement and wire funds. You will receive confirmation of your investment and access to ongoing investor updates.
Ready to learn more?
Contact Byung Kim, Co-Founder & CEO
Forward-looking statements involve risks and uncertainties. Actual results may differ materially. All projections, targets, and timelines presented are management estimates based on current assumptions and are subject to the risks described in the Risk Factors and Regulatory Disclosures pages.